Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020196665 - ANTITUMOR COMPOSITION

Publication Number WO/2020/196665
Publication Date 01.10.2020
International Application No. PCT/JP2020/013454
International Filing Date 25.03.2020
IPC
A61K 31/44 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/4184 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/175 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
17having the group N-C(O)-N or N-C(S)-N, e.g. urea, thiourea, carmustine
175having the group , N-C(O)-N=N- or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
A61K 31/255 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
255of sulfoxy acids or sulfur analogues thereof
A61K 31/675 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
675having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
CPC
A61K 31/175
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
17having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
175having the group , >N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
A61K 31/198
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA],
A61K 31/255
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
255of sulfoxy acids or sulfur analogues thereof
A61K 31/4184
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Applicants
  • OTSUKA PHARMACEUTICAL CO., LTD. [JP]/[JP]
Inventors
  • OHI, Naoto
  • OKUNO, Mitsuhiro
  • TANAKA, Hideo
Agents
  • SAEGUSA & PARTNERS
Priority Data
2019-05702925.03.2019JP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTITUMOR COMPOSITION
(FR) COMPOSITION ANTI-TUMORALE
Abstract
(EN)
An object is to provide a novel combination of antitumor agents that can significantly shrink tumors by synergistic antitumor action without increasing side effects as much as possible. Provided is an antitumor composition comprising the following compound (B) or a salt thereof for use in combination with the following antitumor agent (A): (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) a compound or a salt thereof represented by the following formula (1): wherein R1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group; and m represents an integer of 1 to 3, provided that when m represents 2 or 3, R1 is the same or different.
(FR)
L'invention a pour but de fournir une nouvelle combinaison d'agents anti-tumoraux qui peut induire une diminution significative de la masse tumorale par une action anti-tumorale synergique sans augmenter autant que possible les effets indésirables. L'invention concerne une composition anti-tumorale comportant le composé suivant (B), ou un sel de celui-ci, destiné à être utilisé en association avec l'agent anti-tumorale suivant (A) : (A) au moins un agent anti-tumorale sélectionné dans le groupe constitué des agents alkylants, des molécules ciblant le CD20, des inhibiteurs de la méthylation de l'ADN, des anti-métabolites de type anti-pyrimidine, des anti-métabolites de type anti-purine, des anti-folates, des inhibiteurs de Bcl-2 et des inhibiteurs des tyrosine kinases ; (B) un composé ou un sel de celui-ci représenté par la formule suivante (1) : où R1 représente un atome d'halogène, un groupe aryle, un groupe aryloxy, ou un groupe alkyle à courte chaîne éventuellement substitué par un ou plusieurs atomes d'halogène ; R2 représente un atome d'hydrogène, un atome d'halogène, un groupe alkyle à courte chaîne, ou un groupe alcoxy à courte chaîne ; m représente un nombre entier compris entre 1 et 3, à condition que lorsque m représente 2 ou 3, R1 est identique ou différent.
Latest bibliographic data on file with the International Bureau